DNTH
What one share of Dianthus Therapeutics, Inc. /DE/ holds
Pharmaceutical Preparations
We are a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients living with severe autoimmune diseases.
Dianthus Therapeutics, Inc. /DE/’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$4.11 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$3.33 |
| Dividends | $0.00 |
| Cash and investments | $2.02 |
| Book value | $21.39 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.00 | −$65.15 | $0.93 | −$44.63 | — | −$59.39 |
| 2017 | $0.00 | −$19.12 | $1.18 | −$13.17 | — | −$17.91 |
| 2018 | $0.00 | −$3.13 | $0.42 | −$2.69 | — | $4.37 |
| 2019 | $0.00 | −$2.07 | $0.08 | −$1.63 | — | $3.60 |
| 2020 | — | −$1.71 | $0.01 | −$1.47 | — | $2.97 |
| 2021 | — | −$1.29 | $0.02 | −$1.11 | — | −$0.29 |
| 2022 | — | −$32.57 | $0.36 | −$33.61 | — | −$50.69 |
| 2023 | $0.55 | −$8.45 | $0.02 | −$7.17 | $0.00 | — |
| 2024 | $0.19 | −$2.55 | $0.00 | −$2.35 | $0.00 | $11.33 |
| 2025 | $0.05 | −$4.20 | $0.01 | −$3.35 | $0.00 | $11.42 |